Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
| Revenue (TTM) | $3.46B |
| Gross Profit (TTM) | $2.59B |
| EBITDA | $1.08B |
| Operating Margin | 29.60% |
| Return on Equity | 14.40% |
| Return on Assets | 7.58% |
| Revenue/Share (TTM) | $21.15 |
| Book Value | $45.92 |
| Price-to-Book | 5.90 |
| Price-to-Sales (TTM) | 14.53 |
| EV/Revenue | 10.63 |
| EV/EBITDA | 34.17 |
| Quarterly Earnings Growth (YoY) | 39.50% |
| Quarterly Revenue Growth (YoY) | 17.60% |
| Shares Outstanding | $161.91M |
| Float | $148.28M |
| % Insiders | 8.62% |
| % Institutions | 93.36% |
Volatility is currently expanding
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PLEASANTON, Calif., Oct. 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026.
Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows.
VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.
VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Software opened the year as the market's favorite casualty. The SPDR S&P Software & Services ETF NYSEARCA: XSW and the iShares Expanded Tech-Software Sector ETF BATS: IGV each dropped roughly 25% to 27% in the first quarter alone, as traders priced in a future where artificial intelligence (AI) made subscription software obsolete.
Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswire/ -- At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company, Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.
VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VEEV and any ticker you trade — then tracks every position and per-strategy win rate.
